Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel

References

• Beinjnen JH, Schellens JHM. 2004. Drug interactions in oncology. Lancet Oncol 5(8):489–496.
   PubMedGoogle Scholar
• Bhalla KN, Kumar GN, Walle UK, Ibrado AM, Javed T, Stuart RK, Reed C, Arbuck SG, Walle T. 1999. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res 5(7):1723–1730.
   PubMedGoogle Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. 2003. The conduct of in vitro and in vivo drug–drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43(5):443–469.
   PubMedGoogle Scholar
• Bournique B, Lemarié A. 2002. Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab Disposit 30(11):1149–1152.
   PubMedGoogle Scholar
• Castellano EE, Hodder OJR. 1973. The crystal and Molecular structure of the diterpenoid baccatin V, a naturally occurring oxetan with a taxane skeleton. Acta Crystallographica B 29:2566–2570.
   Web of Science ®Google Scholar
• Cresteil T, Monsarrat B, Alvinerie P, Tréluyer JM, Vieira I, Wright M. 1994. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54(2):386–392.
   PubMedGoogle Scholar
• Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, Gueritte F. 2002. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure–activity relationship. Drug Metab Disposit 30(4):438–445.
   PubMedGoogle Scholar
• Elkharraz K, Faisant N, Guse C, Siepmann F, Arica-Yegin B, Oger JM, Gust R, Goepferich A, Benoit JP, Siepmann J. 2006. Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization. Int J Pharmaceut 314 (2):127–136.
   PubMedGoogle Scholar
• Emoto C, Murase S, Sawada Y, Jones BC, Iwasaki K. 2003. In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalysed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metab Pharmacokinet 18(5):287–295.
   PubMedGoogle Scholar
• Fraier D, Cenacchi V, Frigerio E. 1998. Determination of a new polymer-bound paclitaxel derivative (PNU 166945), free paclitaxel and 7-epipaclitaxel in dog plasma and urine by reversed-phase high-performance liquid chromatography with UV detection. J Chromatograph A 797:295–303.
   PubMed Web of Science ®Google Scholar
• Ge GB, Luan HW, Zhang YY, He YQ, Liu XB, Li Y, Wang ZT, Yang L. 2008. Profiling of yew hair roots from various species using ultra-performance liquid chromatography/electrospray ionization mass spectrometry. Rapid Comm Mass Spectrom 22(15):2315–2323.
   PubMedGoogle Scholar
• Gianni L, KTearns CM, Giani A, Capri G, Viganó L, Lacatelli A, Bonadonna G, Egorin MJ. 1995. Non-linear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationships in humans. J Clin Oncol 13(1):180–190.
   PubMedGoogle Scholar
• Gut I, Ojima I, Vaclavikova R, Simek P, Horsky S, Linhart I, Soucek P, Kondrova E, Kuznetsova LV, Chen J. 2006. Metabolism of new-generation taxanes in human, pig, minipig and rat liver microsomes. Xenobiotica 36(9):772–792.
   PubMedGoogle Scholar
• Huang CHO, Kingston DGI, Magri NF, Samaranayake G. 1986. New taxanes from taxus brevifolia, 2. J Nat Prod 49:665–669.
   PubMed Web of Science ®Google Scholar
• Li J, Liu Y, Zhang JW, Wei H, Yang L. 2006. Characterization of hepatic drug-metabolizing activities of Bama miniature pigs (Sus scrofa domestica): comparison with human enzyme analogs. Comparat Med 6:286–290.
   Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275.
   PubMed Web of Science ®Google Scholar
• MacEachern GJ, Wagner LJ, MacEachern MJ. 1997. Paclitaxel stability in solution. Analyt Chem 69:72–77.
   Google Scholar
• Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, Mross K. 2005. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11(13):4843–4850.
   PubMedGoogle Scholar
• Polasek TM, Elliot DJ, Lewis BC, Miners JO. 2004. Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther 311(3):996–1007.
   PubMedGoogle Scholar
• Nicoletti MI, Colombo T, Rossi C, Monardo C, Stura S, Zucchetti M, Riva A, Morazzoni P, Donati MB, Bombardelli E, D’Incalci M, Giavazzi R. (2000). IDN5109, a taxane with oral bioavailability and potent antitumor activity. Cancer Res 60(4):842–846.
   PubMed Web of Science ®Google Scholar
• Omura T, Sato R. (1964). The carbon monoxide-binding pigment of liver microsomes. I. evidence for its hemoprotein nature. J Biol Chem 239:2370–2385.
   PubMed Web of Science ®Google Scholar
• Rae JM, Soukhova NV, Flockhart DA, Desta Z. (2002). Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Disposit 30(5):525–530.
   PubMedGoogle Scholar
• Rahman A, Korzekwa KR, Grogan J, Gonzalez J, Harris JW. (1994). Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54(21):5543–5546.
   PubMedGoogle Scholar
• Ringel I, Horwitz SB. 1987. Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium. J Pharmacol Exp Ther 242:692–698.
   PubMed Web of Science ®Google Scholar
• Royer I, Alvinerie P, Armand JP, Ho LK, Wright M, Monsarrat B. (1995). Paclitaxel metabolites in human plasma and urine: identification of 6α-hydroxytaxol, 7-epitaxol and taxol hydrolysis products using liquid chromatography/atmospheric-pressure chemical ionization mass spectrometry. Rapid Comm Mass Spectrom 9:495–502.
   PubMedGoogle Scholar
• Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV. 1998. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8(5):391–401.
   PubMedGoogle Scholar
• Sottani C, Minoia C, Colombo A, Zucchetti M, D’Incalci M, Fanelli R. 1997. Structural characterization of mono- and dihydroxylated metabolites of paclitaxel in rat bile using liquid chromatography/ion spray tandem mass spectrometry. Rapid Comm Mass Spectrom 11(9):1025–1032.
   PubMedGoogle Scholar
• Sugahara S, Kajiki M, Kuriyama H, Kobayashi TR. 2002. Paclitaxel delivery systems: the use of amino acid linkers in the conjugation of paclitaxel with carboymethyldextran to create prodrugs. Biol Pharmaceut Bull 25(5):632–641.
   PubMed Web of Science ®Google Scholar
• Sugahara S, Kajiki M, Kuriyama H, Kobayashi TR. 2007. Complete regression of xenografted human carcinomas by a paclitaxel–carboxymethyl dextran conjugate (AZ10992). J Contr Release 117(1):40–50.
   PubMed Web of Science ®Google Scholar
• Tian J, Stella VJ. 2008. Degradation of paclitaxel and related compounds in aqueous solutions I: Epimerization. J Pharmaceut Sci 97:1224–1235.
   PubMed Web of Science ®Google Scholar
• Vaclavikova R, Soucek P, Svobodova L, Anzenbacher P, Simek P, Guengerich FP, Gut I. 2004. Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab Disposit 32(6):666–674.
   PubMedGoogle Scholar
• Venkatakrishnan K, Von Moltke LL, Court MH, Harmatz JS, Crespi CL, Greenblatt DJ. 2000. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Disposit 28(12):1493–1504.
   PubMedGoogle Scholar
• Vivekanandan K, Swamy MG, Prasad S, Mukherjee R, Burman AC. (2006). Identification of isocephalomannine in the presence of cephalomannine isomers and alkali metal ion adducts in a paclitaxel active pharmaceutical ingredient using electrospray tandem mass spectrometry. Rapid Comm Mass Spectrom 20(11):1731–1735.
   PubMedGoogle Scholar
• Walle T, Walle UK, Kumar GN, Bhalla KN. 1995. Taxol metabolism and disposition in cancer patients. Drug Metab Disposit 23(4):506–512.
   PubMedGoogle Scholar
• Walsky RL, Obach RS. 2004. Validated assays for human cytochrome P450 activities. Drug Metab Disposit32 (6):647–660.
   PubMedGoogle Scholar
• Walsky RL, Obach RS, Gaman EA, Gleeson JP, Proctor WR. 2005. Selective inhibition of human cytochrome P450 2C8 by montelukast. Drug Metab Disposit 33(3):413–418.
   PubMedGoogle Scholar
• White RE. 2000. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Ann Rev Pharmacol Toxicol 40:133–157.
   PubMed Web of Science ®Google Scholar
• Xu Q, Trissel LA, Martinez JF. 1994. Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22 or 32°C. Am J Hlth Sys Pharm 51(24):3058–3060.
   Google Scholar
• Zhang JW, Ge GB, Liu Y, Wang LM, Liu XB, Zhang YY, Li W, He YQ, Wang ZT, Sun J, Xiao HB, Yang L. 2008. Taxane’s substituents at C3’ affect its regioselective metabolism: different in vitro metabolism of cephalomannine and paclitaxel. Drug Metab Disposit 36(2):418–426.
   PubMedGoogle Scholar
• Zhang JW, Liu Y, Cheng J, Li W, Ma H, Liu HT, Sun J, Wang LM, He YQ, Wang Y, Wang ZT, Yang L. 2007. Inhibition of human liver cytochrome P450 by star fruit juice. J Pharm Pharmaceut Sci 10(4):496–503.
   PubMedGoogle Scholar